Renaissance Capital logo

GNLX News

Solid tumor biotech Genelux sets terms for $16 million IPO

GNLX

Genelux, a Phase 3 biotech developing oncolytic viral immunotherapies for solid tumors, announced terms for its IPO on Monday. In its latest filing, the company also removed Valuable Capital as an underwriter. The Westlake Village, CA-based company plans to raise $16 million by offering 2.5 million shares at a price range of $6 to $7. At the midpoint of the proposed range,...read more

Solid tumor biotech Genelux files for a $30 million IPO

GNLX

Genelux, a Phase 2 biotech developing oncolytic viral immunotherapies for solid tumors, filed on Friday with the SEC to raise up to $30 million in an initial public offering. Genelux is developing a pipeline of oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The company's lead candidate, Olvi-Vec (olvimulogene...read more

Archived Headlines